This study has two parts, the first part is related to the initial treatment of patients with multiple myeloma (also called induction) and a second part is related to continued long term control of the myeloma (also called maintenance).
The purpose of the first part of the study is to compare the effects, good and/or bad, of a combination of carfilzomib, lenalidomide and dexamethasone with another combination of bortezomib, lenalidomide and dexamethasone, on patients with multiple myeloma to find out which is better. In this study, patients will get either the combination that contains carfilzomib or that containing bortezomib. They will not get both.
Following the initial treatment of multiple myeloma (induction), the second part of the study will examine if it is better to continue lenalidomide until the myeloma comes back or limit it for a defined period of 2 years.
Click here for more information from the National Cancer Institute.